Rangwala Reshma 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 6, 2025
Insider Transaction Report
Form 4
Rangwala Reshma
EVP & Chief Medical Officer
Transactions
- Sale
Common Stock
2025-03-04$6.29/sh−3,587$22,562→ 29,272 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
- [F2]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.